Verified Nov 2026
Other
·
Bedford, Massachusetts
·
Since 1956
Lantheus is a life sciences company that develops diagnostic imaging agents and radiopharmaceuticals, including agents for PET and SPECT scans and ultrasound-enhancing agents. Founded in 1956 and headquartered in Bedford, Massachusetts, the company employs between 1,000 and 5,000 people and is publicly traded on NASDAQ under the ticker LNTH. It serves the medical sector, with its PYLARIFY prostate cancer imaging agent licensed to GE HealthCare for Japan in September 2025. The company also operates in the automotive, electric-vehicle, and industrial equipment industries as recorded.
Lantheus at a glance
Revenue
1.5B
Employees
1,000-5,000
Founded
1956
Headquarters
Bedford, Massachusetts
Ownership
Publicly traded (NASDAQ: LNTH)
Import activity
36
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
36
Named foreign suppliers
7
Top origins
Germany · Belgium · Greece
Shared foreign counterparties do not establish that these companies buy from Lantheus.
What this tells a buyer
Lantheus announced a definitive agreement to merge with Curium on August 3, 2026, and reported its third quarter 2026 financial results on November 5, 2026.
The company's products include PYLARIFY, an imaging agent for prostate cancer, and DEFINITY, which enhances ultrasound imaging for cardiac assessments, and no certifications are listed in the record.
Lantheus completed its acquisition of Life Molecular Imaging in July 2025 and announced in May 2025 that SHINE planned to acquire its SPECT division.
Source: US customs bill-of-lading records and public filings · Last verified Nov 05, 2026
Overview
Lantheus is a life sciences company that develops diagnostic imaging agents and radiopharmaceuticals, including agents for PET and SPECT scans and ultrasound-enhancing agents. Founded in 1956 and headquartered in Bedford, Massachusetts, the company employs between 1,000 and 5,000 people and is publicly traded on NASDAQ under the ticker LNTH. It serves the medical sector, with its PYLARIFY prostate cancer imaging agent licensed to GE HealthCare for Japan in September 2025. The company also operates in the automotive, electric-vehicle, and industrial equipment industries as recorded.
At a glance
Attribute | Detail |
|---|---|
Founded | 1956 |
Headquarters | Bedford, Massachusetts |
Employees | 1,000-5,000 |
Revenue | 1.5B |
Ownership | Publicly traded (NASDAQ: LNTH) |
What Lantheus makes
The company's products include PYLARIFY, an imaging agent for prostate cancer, and DEFINITY, which enhances ultrasound imaging for cardiac assessments, and no certifications are listed in the record.
Trade and customs footprint
Lantheus announced a definitive agreement to merge with Curium on August 3, 2026, and reported its third quarter 2026 financial results on November 5, 2026. US customs bill-of-lading records list 36 inbound shipments across 7 foreign suppliers, with top origins including Germany · Belgium · Greece.
Latest developments
2026-11-05 — Lantheus Reports Third Quarter 2026 Financial Results (globenewswire.com)
2026-08-03 — Curium Announces Definitive Agreement to Merge with Lantheus | Lantheus Holdings, Inc. (lantheus.com)
2025-09-24 — Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan | Lantheus Holdings, Inc. (lantheus.com)
2025-07-22 — Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D | Lantheus Holdings, Inc. (lantheus.com)
2025-05-06 — SHINE Announces Plan to Acquire Lantheus’ SPECT Division (shinefusion.com)
2025-04-01 — Lantheus Completes Acquisition of Evergreen Theragnostics | Lantheus Holdings, Inc. (lantheus.com)
Company details
Lantheus completed its acquisition of Life Molecular Imaging in July 2025 and announced in May 2025 that SHINE planned to acquire its SPECT division. Lantheus was founded in 1956, has an estimated 1,000-5,000 employees, and is headquartered in Bedford, Massachusetts.
Frequently asked questions
What does Lantheus do?
Lantheus is a life sciences company that develops diagnostic imaging agents and radiopharmaceuticals, including agents for PET and SPECT scans and ultrasound-enhancing agents. Founded in 1956 and headquartered in Bedford, Massachusetts, the company employs between 1,000 and 5,000 people and is publicly traded on NASDAQ under the ticker LNTH. It serves the medical sector, with its PYLARIFY prostate cancer imaging agent licensed to GE HealthCare for Japan in September 2025. The company also operates in the automotive, electric-vehicle, and industrial equipment industries as recorded.
Where is Lantheus headquartered?
Lantheus is headquartered in Bedford, Massachusetts (201 Burlington Rd, Bedford, Massachusetts, 01730-1452).
When was Lantheus founded?
Lantheus was founded in 1956.
How big is Lantheus?
Lantheus has an estimated 1,000-5,000 employees, with revenue in the 1.5B range.
Is Lantheus publicly traded?
Publicly traded (NASDAQ: LNTH). Public financial figures are drawn from its filings.
Does Lantheus import from overseas suppliers?
US customs bill-of-lading records show 36 inbound shipments for Lantheus, with top origins including Germany · Belgium · Greece.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.